Assessment and management of patients with portopulmonary hypertension undergoing liver transplantation

•PoPH occurs in 5-8.5% of LT candidates and has important implications for the eligibility, feasibility and outcomes of LT.•Early recognition of PoPH is key - screen all LT candidates with TTE and confirm diagnosis and assess severity with RHC.•PAH-specific pharmacological therapy can improve haemodynamics, facilitate eligibility for LT and reduce mortality.•Improvement in pulmonary haemodynamics and the discontinuation of PAH-specific pharmacotherapy is often achievable post-LT.•Further research required to define optimal risk stratification and pharmacotherapy strategies in LT candidates with PoPH.